...
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis
【24h】

Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis

机译:监测,流行病学和最终结果分析中接受放射治疗的非典型性类畸形横纹肌瘤的生存结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Atypical teratoid rhabdoid tumor (ATRT) is a rare central nervous system malignancy with a poor prognosis that affects mostly young children. Although radiotherapy (RT) historically has been delayed in patients aged <3 years, emerging evidence suggests a role for RT to achieve long-term survivorship. Clinical features and age-dependent trends of RT use were evaluated for patients with ATRT. Methods: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to identify 144 patients with ATRT from 1973 to 2008. The primary endpoint was median overall survival (OS). Clinical and treatment variables were assessed for an association with OS using Cox proportional hazards models. Landmark analysis was used to correct for immortal time bias of adjuvant RT. Results: The median age at diagnosis was 1 year (range, 0-67 years). Gross total resection of the primary tumor was achieved in 39% of patients, and 33% of patients received RT. From 1992 to 2008, RT use increased 2.4-fold in patients aged a≤3 years. The median OS for was 10 months. In multivariate analyses, metastatic disease (hazard ratio, 2.83; 95% confidence interval, 1.53-5.23; P =.001) and RT (hazard ratio, 0.10; 95% confidence interval, 0.01-0.73; P =.02) were identified as independent predictors of survival. Landmark analysis confirmed a robust association between RT use and survival, which was attenuated in patients ages 4 to 17 years compared with younger patients. Conclusions: The current results indicated that RT may offer a significant survival benefit for patients with ATRT and that patients aged a;circ3 years may derive more benefit from initial RT compared with older children. The authors concluded that prospective clinical trials are needed to examine the role of RT in the initial management of ATRT in patients aged <3 years.
机译:背景:非典型性teratoid横纹肌瘤(ATRT)是一种罕见的中枢神经系统恶性肿瘤,预后较差,主要影响幼儿。尽管历来<3岁的患者放射治疗(RT)一直被推迟,但新出现的证据表明RT可以实现长期生存。评估了ATRT患者的临床特征和年龄依赖性的RT使用趋势。方法:使用美国国家癌症研究所的监视,流行病学和最终结果数据库确定了1973年至2008年之间的144例ATRT患者。主要终点是中位总体生存率(OS)。使用Cox比例风险模型评估了与OS相关的临床和治疗变量。使用地标分析来校正佐剂RT的不朽时间偏差。结果:诊断时的中位年龄为1岁(范围0-67岁)。 39%的患者实现了原发肿瘤的大体总切除,而33%的患者接受了RT。从1992年到2008年,≤3岁的患者使用RT的人数增加了2.4倍。 OS的中位数为10个月。在多变量分析中,确定了转移性疾病(危险比,2.83; 95%置信区间,1.53-5.23; P = .001)和RT(危险比,0.10; 95%置信区间,0.01-0.73; P = .02)。作为生存的独立预测指标。具有里程碑意义的分析证实,RT使用与生存之间存在密切的关联,与年轻患者相比,年龄在4至17岁之间的关联减弱。结论:目前的结果表明,RT可以为ATRT患者提供显着的生存获益,而3岁左右的患者与年龄较大的儿童相比,可以从初始RT获得更多的获益。作者得出结论,需要进行前瞻性临床试验,以检查RT在3岁以下患者ATRT初始治疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号